Búsqueda | Biblioteca Virtual en Salud

1.

HCV disease burden and population segments in Switzerland.

Bihl, Florian; Bruggmann, Philip; Castro Batänjer, Erika; Dufour, Jean-Francois; Lavanchy, Daniel; Müllhaupt, Beat; Negro, Francesco; Razavi, Homie; Scheidegger, Claude; Semela, David; Semmo, Nasser; Blach, Sarah.

Liver Int ; 42(2): 330-339, 2022 02.

Artículo en Inglés | MEDLINE | ID: mdl-34839578

2.

Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus.

Wiersma, Steven T; McMahon, Brian; Pawlotsky, Jean-Michel; Thio, Chloe L; Thursz, Mark; Lim, Seng Gee; Ocama, Ponsiano; Esmat, Gamal; Mendy, Maimuna; Maimuna, Mendy; Bell, David; Vitoria, Marco; Eramova, Irina; Lavanchy, Daniel; Dusheiko, Geoff.

Liver Int ; 31(6): 755-61, 2011 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-21645206

3.

The global burden of hepatitis C.

Lavanchy, Daniel.

Liver Int ; 29 Suppl 1: 74-81, 2009 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-19207969

4.

Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?

Müllhaupt, Beat; Bruggmann, Philip; Bihl, Florian; Blach, Sarah; Lavanchy, Daniel; Razavi, Homie; Robbins Scott, Sarah; Semela, David; Negro, Francesco.

PLoS One ; 13(12): e0209374, 2018.

Artículo en Inglés | MEDLINE | ID: mdl-30596701

5.

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.

Bruggmann, Philip; Blach, Sarah; Deltenre, Pierre; Fehr, Jan; Kouyos, Roger; Lavanchy, Daniel; Müllhaupt, Beat; Rauch, Andri; Razavi, Homie; Schmid, Patrick; Semela, David; Stoeckle, Marcel; Negro, Franco.

Swiss Med Wkly ; 147: w14543, 2017.

Artículo en Inglés | MEDLINE | ID: mdl-29120012

6.

Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report.

FitzSimons, David; Hendrickx, Greet; Hallauer, Johannes; Larson, Heidi; Lavanchy, Daniel; Lodewyckx, Ina; Shouval, Daniel; Ward, John; Van Damme, Pierre.

Hepatol Med Policy ; 1: 16, 2016.

Artículo en Inglés | MEDLINE | ID: mdl-30288319

7.

Vaccine safety controversies and the future of vaccination programs.

François, Guido; Duclos, Philippe; Margolis, Harold; Lavanchy, Daniel; Siegrist, Claire-Anne; Meheus, André; Lambert, Paul-Henri; Emiroglu, Nedret; Badur, Selim; Van Damme, Pierre.

Pediatr Infect Dis J ; 24(11): 953-61, 2005 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-16282928

8.

Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland.

Bruggmann, Philip; Negro, Francesco; Bihl, Florian; Blach, Sarah; Lavanchy, Daniel; Müllhaupt, Beat; Razavi, Homie; Semela, David.

Swiss Med Wkly ; 145: w14221, 2015.

Artículo en Inglés | MEDLINE | ID: mdl-26715488

9.

Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland.

Müllhaupt, Beat; Bruggmann, Philip; Bihl, Florian; Blach, Sarah; Lavanchy, Daniel; Razavi, Homie; Semela, David; Negro, Francesco.

PLoS One ; 10(6): e0125214, 2015.

Artículo en Inglés | MEDLINE | ID: mdl-26107467

10.

Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.

Pfeil, Alena M; Reich, Oliver; Guerra, Ines M; Cure, Sandrine; Negro, Francesco; Müllhaupt, Beat; Lavanchy, Daniel; Schwenkglenks, Matthias.

PLoS One ; 10(5): e0126984, 2015.

Artículo en Inglés | MEDLINE | ID: mdl-25974722

11.

Hepatitis B virus transmission in organ, tissue, and cell transplantation.

Lavanchy, Daniel.

Gastroenterology ; 135(4): 1041-3, 2008 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-18786537

12.

Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection.

Fretz, Rainer; Negro, Francesco; Bruggmann, Philip; Lavanchy, Daniel; De Gottardi, Andrea; Pache, Isabelle; Masserey Spicher, Virginie; Cerny, Andreas.

Swiss Med Wkly ; 143: w13793, 2013.

Artículo en Inglés | MEDLINE | ID: mdl-23740193

13.

Viral hepatitis: global goals for vaccination.

Lavanchy, Daniel.

J Clin Virol ; 55(4): 296-302, 2012 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-22999800

14.

WITHDRAWN: Viral Hepatitis: global goals for vaccination.

Lavanchy, Daniel.

J Clin Virol ; 2009 Jul 03.

Artículo en Inglés | MEDLINE | ID: mdl-19577511

15.

Chronic viral hepatitis as a public health issue in the world.

Lavanchy, Daniel.

Best Pract Res Clin Gastroenterol ; 22(6): 991-1008, 2008.

Artículo en Inglés | MEDLINE | ID: mdl-19187863

16.

Hepatitis C virus infection trends in Italy.

Lavanchy, Daniel.

Hepat Mon ; 12(1): 46-7, 2012 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-22451844

17.

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants.

Fitzsimons, David; François, Guido; Hall, Andrew; McMahon, Brian; Meheus, André; Zanetti, Alessandro; Duval, Bernard; Jilg, Wolfgang; Böcher, Wulf Otto; Lu, Sheng-Nan; Akarca, Ulus; Lavanchy, Daniel; Goldstein, Susan; Banatvala, Jangu; Damme, Pierre Van.

Vaccine ; 23(32): 4158-66, 2005 Jul 14.

Artículo en Inglés | MEDLINE | ID: mdl-15964484

18.

Public health measures in the control of viral hepatitis: a World Health Organization perspective for the next millennium.

Lavanchy, Daniel.

J Gastroenterol Hepatol ; 17 Suppl: S452-9, 2002 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-12534777

19.

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

de Franchis, Roberto; Hadengue, Antoine; Lau, George; Lavanchy, Daniel; Lok, Anna; McIntyre, Neil; Mele, Alfonso; Paumgartner, Gustav; Pietrangelo, Antonello; Rodés, Juan; Rosenberg, William; Valla, Dominique.

J Hepatol ; 39 Suppl 1: S3-25, 2003.

Artículo en Inglés | MEDLINE | ID: mdl-14708673

20.

Hepatite C: estratégias de saúde pública / Hepatitis C: public health strategies

Lavanchy, Daniel; Gavinio, Pilar; Kitler, Mary Ellen.

In. Focaccia, Roberto. Tratado de hepatites virais. São Paulo, Atheneu, 2002. p.315-323, mapas, tab.

Monografía en Portugués | LILACS, SES-SP | ID: lil-334837

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

HCV disease burden and population segments in Switzerland.

Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus.

The global burden of hepatitis C.

Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.

Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report.

Vaccine safety controversies and the future of vaccination programs.

Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland.

Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland.

Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.

Hepatitis B virus transmission in organ, tissue, and cell transplantation.

Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection.

Viral hepatitis: global goals for vaccination.

WITHDRAWN: Viral Hepatitis: global goals for vaccination.

Chronic viral hepatitis as a public health issue in the world.

Hepatitis C virus infection trends in Italy.

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants.

Public health measures in the control of viral hepatitis: a World Health Organization perspective for the next millennium.

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

Hepatite C: estratégias de saúde pública / Hepatitis C: public health strategies